Article info

Download PDFPDF

690 Correlates of poor response to neoadjuvant anti-PD-1 therapy in hepatocellular carcinoma (HCC) include WNT pathway activation and loss of HLA expression
Free

Authors

Citation

Kundu K, Fiaschi N, Wang W, et al
690 Correlates of poor response to neoadjuvant anti-PD-1 therapy in hepatocellular carcinoma (HCC) include WNT pathway activation and loss of HLA expression

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.